GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer Ruchika Sharma21 Jan 2025 1:30 PM ISTLondon: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy...
Jemperli bags USFDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer: GSK Ruchika Sharma16 Dec 2024 1:30 PM ISTLondon: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Jemperli...
US FDA expands Jemperli plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma2 Aug 2024 10:00 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and...
GSK application for expanded indication of Jemperli plus chemotherapy accepted by USFDA for priority review Ruchika Sharma25 April 2024 12:40 PM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for...
Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma20 Dec 2023 2:30 PM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
GSK gets European Commission marketing authorisation for Jemperli, chemotherapy combo for endometrial cancer Ruchika Sharma13 Dec 2023 3:30 PM ISTLondon: GSK plc has announced the European Commission (EC) has granted marketing authorisation for Jemperli (dostarlimab) in combination with...
Phase III trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma31 Oct 2023 11:35 AM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
GSK gets positive EMA Committee opinion recommending approval of Jemperli plus chemotherapy for endometrial cancer Ruchika Sharma19 Oct 2023 2:41 PM ISTUK: GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
GSK gets USFDA nod for Jemperli plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer Ruchika Sharma1 Aug 2023 11:30 AM ISTJemperli is already approved in the US as monotherapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or...
GSK supplemental application for Jemperli plus chemotherapy accepted by USFDA for endometrial cancer Ruchika Sharma6 Jun 2023 3:28 PM ISTJemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands...
GSK gets full USFDA nod for Jemperli to treat recurrent or advanced mismatch repair deficient endometrial cancer Ruchika Sharma11 Feb 2023 11:30 AM ISTJemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands...
GSK gets speedy USFDA nod for Jemperli Ruchika Sharma21 Aug 2021 11:00 AM ISTUK: GlaxoSmithKline (GSK) plc has recently announced that the US Food and Drug Administration (USFDA) approved a new indication for JEMPERLI...
